Medical Device Manufacturing & Sterilization Services
Strategic Profile
With 80% of revenue being recurring from consumables and services, STERIS benefits from stable revenue streams essential for funding innovation and maintaining competitive edge. Once a hospital installs a STERIS sterilization system or an AST client validates a medical device using a specific STERIS process, the cost and regulatory burden of switching to a competitor is extremely high, creating strong customer lock-in and competitive moat.
Cyborg Score Rationale
With over 93% institutional ownership, STERIS is recognized as a critical infrastructure player underpinning the entire healthcare, pharmaceutical, and medical device supply chain. The company's high recurring revenue base, strategic focus on core competencies post-dental divestiture, and strong institutional support indicate solid operational execution.
Top Insights
80% recurring revenue from consumables and services provides stability for sustained innovation
High customer switching costs create competitive moat in hospital and medical device sterilization
Divested dental segment in FY2025 to focus capital on higher-growth core infection prevention business
18,000+ global workforce with strong institutional ownership (93%) demonstrates operational scale and investor confidence
Named Competitors
Getinge — Sterilization and surgical workflow solutions provider
Cantel Medical — Infection prevention products for endoscopy, dental and dialysis
ContinuumRx — Outsourced sterilization and surgical instrument services
Recent Developments
(February 2026) STERIS announced financial results for fiscal 2026 third quarter
(January 2026) STERIS announced dividend of $0.63 per share
(Q2 FY2026) Company reported $1.5 billion revenue in second quarter, reflecting strong market demand for infection prevention solutions
Open the full interactive STERIS plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.